Corteva, Inc. has surged 32.7% year-to-date following a first-quarter 2026 earnings beat and a stronger operating outlook. Operating earnings reached $1.50 per share, up 32.7% year over year and topping consensus by 27.1%, while net sales rose 11% to $4.91 billion, exceeding expectations by 5.6%. Operating EBITDA advanced 21% to $1.44 billion, with margins expanding roughly 240 basis points to more than 29%. The stock now trades at 22.52 times forward earnings, above its five-year median of 19.04 times and the Zacks sub-industry average of 15.68 times, leaving less room for disappointment. Corteva remains on track to separate its Seed and Crop Protection businesses in the fourth quarter of 2026, incurring one-time separation costs of roughly $350 million and $50 million in net dis-synergies, while the board approved an approximately $1.5 billion pretax pension contribution to support investment-grade credit profiles for both entities. The innovation pipeline includes new Crop Protection products approaching $2 billion in 2026 revenues, a proprietary hybrid wheat launch in 2027 tied to a $1 billion long-term opportunity, and a Bayer licensing agreement expected to generate roughly $1 billion in incremental revenues over the next decade. CTVA carries a Zacks Rank of 2, or Buy, with a 1.3% upward revision in the current fiscal year earnings estimate over the past four weeks and a Momentum Score of A, though its Value Score of D and Growth Score of D indicate the appeal is not broad-based.
Corteva IncCorteva reported Q1 earnings beat and raised outlook, with EPS up 32.7% and sales up 11%.
FMC Corporation